Article
Immunology
Carlos G. Grijalva, Leora R. Feldstein, H. Keipp Talbot, Michael Aboodi, Adrienne H. Baughman, Samuel M. Brown, Jonathan D. Casey, Heidi L. Erickson, Matthew C. Exline, D. Clark Files, Kevin W. Gibbs, Adit A. Ginde, Michelle N. Gong, Natasha Halasa, Akram Khan, Christopher J. Lindsell, Samuel K. Nwosu, Ithan D. Peltan, Matthew E. Prekker, Todd W. Rice, Nathan Shapiro, Jay S. Steingrub, William B. Stubblefield, Mark W. Tenforde, Manish M. Patel, Wesley H. Self
Summary: This study evaluated the effectiveness of the influenza vaccine in preventing severe acute respiratory infection associated with influenza during the 2019-2020 season. The results showed that the vaccine reduced severe influenza-associated illness by 32%, with higher effectiveness observed in young adults.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Infectious Diseases
Alexander Domnich, Donatella Panatto, Elena Pariani, Christian Napoli, Maria Chironna, Ilaria Manini, Caterina Rizzo, Andrea Orsi, Giancarlo Icardi
Summary: This study aimed to compare the relative vaccine effectiveness of MF59-adjuvanted trivalent vaccine and non-adjuvanted quadrivalent vaccine against severe laboratory-confirmed influenza. The results showed that the MF59-adjuvanted vaccine was more effective in preventing severe acute respiratory infection.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Immunology
Kailey Hughes, Donald B. Middleton, Mary Patricia Nowalk, Goundappa K. Balasubramani, Emily T. Martin, Manjusha Gaglani, H. Keipp Talbot, Manish M. Patel, Jill M. Ferdinands, Richard K. Zimmerman, Fernanda P. Silveira
Summary: This study evaluated the vaccine effectiveness against influenza hospitalization among immunocompromised adults during the 2017-2018 influenza season. The results showed that while immunocompromised adults had a higher vaccination rate, their protection against influenza was lower, with a vaccine effectiveness of 33% in the overall adult population. Further research is needed to assess vaccine effectiveness among different immunocompromising conditions and explore ways to improve effectiveness for immunocompromised individuals.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Infectious Diseases
Wen-Qiang He, Christopher Gianacas, David J. Muscatello, Anthony T. Newall, Peter McIntyre, Allen C. Cheng, Bette Liu
Summary: This study suggests that influenza vaccine is effective in preventing antibiotic prescriptions for influenza-like illness (ILI) in low-risk adults aged 40 and above, but not in other subgroups.
JOURNAL OF INFECTION
(2022)
Article
Immunology
Kelsey L. Lytle, Sean P. Collins, Leora R. Feldstein, Adrienne H. Baughman, Samuel M. Brown, Jonathan D. Casey, Heidi L. Erickson, Matthew C. Exline, D. Clark Files, Kevin W. Gibbs, Adit A. Ginde, Michelle N. Gong, Carlos G. Grijalva, Akram Khan, Christopher J. Lindsell, Ithan D. Peltan, Matthew E. Prekker, Todd W. Rice, Nathan I. Shapiro, Jay S. Steingrub, William B. Stubblefield, Mark W. Tenforde, Kelsey N. Womack, Manish M. Patel, Wesley H. Self
Summary: This study investigated influenza vaccination uptake among hospitalized patients in the US, finding that a significant proportion of unvaccinated individuals cited perceived vaccine ineffectiveness or risk as reasons for not getting vaccinated. Factors associated with not being vaccinated included lack of medical insurance and being non-White or Hispanic. Recommendations for improving influenza vaccination uptake in the US include educational programs on vaccine safety and effectiveness, as well as enhancing vaccine access for marginalized populations.
Article
Immunology
Donatella Panatto, Alexander Domnich, Maria Chironna, Daniela Loconsole, Christian Napoli, Alessandra Torsello, Ilaria Manini, Emanuele Montomoli, Elena Pariani, Silvana Castaldi, Andrea Orsi, Giancarlo Icardi
Summary: This study investigated the epidemiology of severe acute respiratory infections (SARI) among Italian adults and estimated the effectiveness of the 2021/22 season influenza vaccine. The results showed that influenza cases were mostly detected among non-vaccinated individuals, indicating a protective effect of influenza vaccination.
Article
Immunology
Constantina Boikos, Mahrukh Imran, Van Hung Nguyen, Thierry Ducruet, Gregg C. Sylvester, James A. Mansi
Summary: MF59(R)-adjuvanted trivalent inactivated influenza vaccine (aIIV3) and high-dose trivalent inactivated influenza vaccine (HD-IIV3) demonstrate enhanced immune response in older adults compared to standard, quadrivalent inactivated influenza vaccines (IIV4). The study shows that aIIV3 is more effective than IIV4 in preventing influenza-related medical encounters in both the 2017-2018 and 2018-2019 seasons, with HD-IIV3 showing comparable effectiveness.
Article
Immunology
Willem R. Miellet, Janieke van Veldhuizen, Mioara A. Nicolaie, Rob Mariman, Hester J. Bootsma, Thijs Bosch, Nynke Y. Rots, Elisabeth A. M. Sanders, Josine van Beek, Krzysztof Trzcinski
Summary: Influenza-like illness exacerbates pneumococcal colonization in older adults, with this effect persisting beyond recovery from the illness.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Immunology
Hannah Chung, Michael A. Campitelli, Sarah A. Buchan, Aaron Campigotto, Branson Chen, Natasha S. Crowcroft, Vinita Dubey, Jonathan B. Gubbay, Timothy Karnauchow, Kevin Katz, Allison J. McGeer, J. Dayre McNally, Samira Mubareka, Michelle Murti, David C. Richardson, Laura C. Rosella, Kevin L. Schwartz, Marek Smieja, George Zahariadis, Jeffrey C. Kwong
Summary: The effectiveness of influenza vaccine against laboratory-confirmed influenza was similar between statin users and nonusers. However, statin users had a higher risk of influenza infection compared to nonusers, regardless of vaccination status. This study suggests that statin use may affect the effectiveness of influenza vaccine and increase the risk of influenza infection.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Immunology
Hannah Chung, Sarah A. Buchan, Aaron Campigotto, Michael A. Campitelli, Natasha S. Crowcroft, Vinita Dubey, Jonathan B. Gubbay, Timothy Karnauchow, Kevin Katz, Allison J. McGeer, J. Dayre McNally, Samira Mubareka, Michelle Murti, David C. Richardson, Laura C. Rosella, Kevin L. Schwartz, Marek Smieja, George Zahariadis, Jeffrey C. Kwong
Summary: This study estimated the effectiveness of influenza vaccine against mortality in older adults following laboratory-confirmed influenza in Ontario, Canada. The results showed that the vaccine had a significant impact on reducing all-cause mortality, especially during the 2014-2015 influenza season. Factors such as influenza subtype and COPD also played a role in mortality outcomes.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Public, Environmental & Occupational Health
Lisa P. Spees, Caitlin B. Biddell, Rebekah S. M. Angove, Kathleen D. Gallagher, Eric Anderson, Ashley Christenbury, Gabrielle Rocque, Stephanie B. Wheeler
Summary: Despite interventions to increase COVID-19 vaccination, differences in uptake persist, indicating that these interventions may not address barriers faced by certain populations. A survey of chronically ill patients demonstrated that informational and attitudinal barriers were more prevalent than logistical or structural access barriers, and attitudinal barriers were associated with vaccine uptake. Interventions should target attitudinal barriers among patients with chronic illness, particularly those without a usual source of care.
FRONTIERS IN PUBLIC HEALTH
(2023)
Article
Immunology
Stephanie James, Robert C. Haight, Cassandra Hanna, Lindsey Furton
Summary: This study aims to understand the level of protection against influenza in adults with Down syndrome following vaccination. The results suggest that adults with Down syndrome had increased antibody concentration but decreased titer to a specific strain of influenza compared to controls. Further research on B- and T-cell function in this population is needed, and high-dose influenza vaccine may benefit them.
Article
Immunology
Mahrukh Imran, Juan Puig-Barbera, Justin R. Ortiz, Lorena Lopez-Gonzalez, Alex Dean, Machaon Bonafede, Mendel Haag
Summary: This study found that during the 2019-2020 US influenza season, the mammalian cell-based quadrivalent inactivated influenza vaccine was associated with lower rates of cardiorespiratory hospitalizations, respiratory hospitalizations, and influenza hospitalizations compared to the egg-based quadrivalent inactivated influenza vaccine.
OPEN FORUM INFECTIOUS DISEASES
(2023)
Article
Public, Environmental & Occupational Health
I. Tsiligianni, I Bouloukaki, G. Papazisis, A. Paganas, E. Chatzimanolis, M. Kalatharas, I. Platakis, I. Tirodimos, T. Dardavesis, Z. Tsimtsiou
Summary: Insufficient adult vaccination coverage rates remain an international challenge. This study explored vaccination coverage and predictors of vaccine uptake in Greece and found that perception of disease risk, concerns about side-effects and efficacy, and mistrust in pharmaceutical companies were common factors associated with vaccine uptake. The strongest predictor of vaccination status was the doctor's recommendation, and being well-informed about each vaccine also influenced uptake.
Review
Geriatrics & Gerontology
Jessica Bartoszko, Mark Loeb
Summary: Influenza is an acute respiratory infection that can be prevented through vaccination. Despite older adults having the highest burden of influenza infection, vaccine effectiveness is lowest in this population due to immune senescence. Possible strategies to tackle this issue include adjuvant and high-dose vaccines, as well as increasing vaccine uptake to induce herd immunity.
AGING CLINICAL AND EXPERIMENTAL RESEARCH
(2021)